Yakup Ergün
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Yakup Ergün
May 26, 2024, 10:50 |
Opinion
Yakup Ergün: The policy of some journals to collect accepted letters under a single heading is quite unfair
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared on X: “The policy…
May 26, 2024, 08:25 |
Blog
Paolo Tarantino: Looking forward to presenting this analysis of T-DXd in 1500 patients with MBC
Paolo Tarantino shared a post by Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital,…
May 25, 2024, 01:35 |
Insight
Yakup Ergün: An excellent review on the gonoadotoxicity of new anticancer agents
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared on X/Twitter: "Assessing risks…
May 23, 2024, 09:20 |
Blog
Yakup Ergün Summarizes Final Results of RIGHT Choice
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on X:…
May 21, 2024, 15:41 |
Insight
Yakup Ergün: A valuable retrospective study on PD-L1 alteration after NAC in TNBC
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…
Apr 9, 2024, 09:20 |
Insight
Yakup Ergün: Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases - SENOMAC trial
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…
Aug 14, 2023, 17:14 |
Insight
Yakup Ergün: Breast-cancer screening gets a boost from Artificial Intelligence (AI)
In a Twitter post by Yakup Ergün, Medical Oncologist, it says: "Breast-cancer screening gets a…
1
2
All:
17
Posts:
11 - 20
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube